Galapont Capital was founded in 2012. The focus of the partnership is providing strategic growth funding and Board support for companies bringing transformative and commercially scalable solutions to unsolved problems and under-served markets in healthcare & life sciences:
Stage: Initial investment is 12-18 months prior to major inflection point of rapid growth in value and commercial scale.
Primary Focus: Life sciences and healthcare companies best positioned to drive or enable rapid transformation to next generation consumer demand and value impact driven healthcare 2021-2030. Key therapeutic areas include rheumatic autoimmune and neurological autoimmune diseases, Long COVID, neurodegeneration, and brain health.
Company Attributes: Leadership position in dramatically under-served market; deep understanding of the industry ecosystem and competitive landscape; capacity to attract top talent across all disciplines; culture that embraces technology, data, innovation, and human capital and communication; prepared to scale quickly through operational excellence, acquisitions, partnerships, and/or licensing; commitment to strong governance; the Board, founder, officers, major investors aligned on operating plan and return objectives.
Investment Approach: Lead or co-lead new investment round and serve on Board of Directors. Help de-risk final transition to major value and growth inflection point. Support parallel path to IPO or M&A.